Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)
A Randomized Phase I/II Study to Assess the Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-Level Deep Venous Thrombosis
Sponsor: GlycoMimetics Incorporated
Terminated
The trial was funded in part by a grant; the trial closed when the grant ended.
Other terminated trials from GlycoMimetics Incorporated
Other Deep Venous Thrombosis trials with similar outcome
A PHASE1/PHASE2 clinical study on Deep Venous Thrombosis, this trial is terminated or withdrawn. The trial is conducted by GlycoMimetics Incorporated and has accumulated 9 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE1_PHASE2
-
Jul 2019 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Completed → Terminated
▶ Show 4 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE1_PHASE2
-
May 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlycoMimetics Incorporated
- University of Michigan
For direct contact, visit the study record on ClinicalTrials.gov .